DENALI THERAPEUTICS INC (DNLI) Stock Price & Overview
NASDAQ:DNLI • US24823R1059
Current stock price
The current stock price of DNLI is 20.57 USD. Today DNLI is down by -0.63%. In the past month the price increased by 7.25%. In the past year, price increased by 35.78%.
DNLI Key Statistics
- Market Cap
- 3.262B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.97
- Dividend Yield
- N/A
DNLI Stock Performance
DNLI Stock Chart
DNLI Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to DNLI. When comparing the yearly performance of all stocks, DNLI is one of the better performing stocks in the market, outperforming 85.79% of all stocks.
DNLI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to DNLI. DNLI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
DNLI Earnings
DNLI Forecast & Estimates
25 analysts have analysed DNLI and the average price target is 32.95 USD. This implies a price increase of 60.2% is expected in the next year compared to the current price of 20.57.
For the next year, analysts expect an EPS growth of 4.15% and a revenue growth 3761.96% for DNLI
DNLI Groups
Sector & Classification
DNLI Financial Highlights
Over the last trailing twelve months DNLI reported a non-GAAP Earnings per Share(EPS) of -2.97. The EPS decreased by -11.24% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -44.77% | ||
| ROE | -50.56% | ||
| Debt/Equity | 0.01 |
DNLI Ownership
DNLI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.8 | 388.432B | ||
| AMGN | AMGEN INC | 16.04 | 197.413B | ||
| GILD | GILEAD SCIENCES INC | 16.4 | 179.993B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.21 | 119.226B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.95 | 78.843B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.01 | 41.564B | ||
| INSM | INSMED INC | N/A | 30.069B | ||
| BIIB | BIOGEN INC | 11.29 | 26.644B | ||
| NTRA | NATERA INC | N/A | 26.624B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.95 | 23.498B | ||
| MRNA | MODERNA INC | N/A | 20.758B | ||
| EXAS | EXACT SCIENCES CORP | 340.74 | 19.77B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.798B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About DNLI
Company Profile
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. The company is headquartered in South San Francisco, California and currently employs 503 full-time employees. The company went IPO on 2017-12-08. The firm is focused on developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases. The company has developed a technology, called the TransportVehicle (TV), to address the BBB challenge. Its advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (MPS II or Hunter syndrome). Its TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo syndrome) and DNL593 (PTV:PGRN) for frontotemporal dementia-granulin (FTD-GRN). Its small-molecule clinical development portfolio includes BIIB122/DNL151 (small molecule LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (small molecule eIF2B activator) for amyotrophic lateral sclerosis (ALS). The company is also exploring programs in oncology, inflammation, and other diseases.
Company Info
IPO: 2017-12-08
DENALI THERAPEUTICS INC
161 Oyster Point Blvd.
South San Francisco CALIFORNIA 94080 US
CEO: Ryan J. Watts
Employees: 503
Phone: 16508668547
DENALI THERAPEUTICS INC / DNLI FAQ
What does DENALI THERAPEUTICS INC do?
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. The company is headquartered in South San Francisco, California and currently employs 503 full-time employees. The company went IPO on 2017-12-08. The firm is focused on developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases. The company has developed a technology, called the TransportVehicle (TV), to address the BBB challenge. Its advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (MPS II or Hunter syndrome). Its TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo syndrome) and DNL593 (PTV:PGRN) for frontotemporal dementia-granulin (FTD-GRN). Its small-molecule clinical development portfolio includes BIIB122/DNL151 (small molecule LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (small molecule eIF2B activator) for amyotrophic lateral sclerosis (ALS). The company is also exploring programs in oncology, inflammation, and other diseases.
Can you provide the latest stock price for DENALI THERAPEUTICS INC?
The current stock price of DNLI is 20.57 USD. The price decreased by -0.63% in the last trading session.
Does DENALI THERAPEUTICS INC pay dividends?
DNLI does not pay a dividend.
How is the ChartMill rating for DENALI THERAPEUTICS INC?
DNLI has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Is DENALI THERAPEUTICS INC (DNLI) expected to grow?
The Revenue of DENALI THERAPEUTICS INC (DNLI) is expected to grow by 3761.96% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the ownership structure of DENALI THERAPEUTICS INC (DNLI)?
You can find the ownership structure of DENALI THERAPEUTICS INC (DNLI) on the Ownership tab.
What is the Short Interest ratio of DENALI THERAPEUTICS INC (DNLI) stock?
The outstanding short interest for DENALI THERAPEUTICS INC (DNLI) is 9.5% of its float.